advertisement
Study gives "troubling" results about Vytorin
A new trial on the cholesterol drug Vytorin has produced mixed results that experts say are "troubling." In the study, Vytorin--which is a combination of Zetia and Zocor--was effective at lowering the risk of ischemic events. But investigators say the drug did not slow the progression of aortic valve stenosis--which causes blockages in heart valves--or reduce the overall risk of major cardiovascular events better than a placebo. Researchers also found that the rate of new cancers was 50 percent higher in study patients taking Vytorin.
(MedPage Today) UPDATED 07/21/2008Click here to read the full story
Conditions: | atherosclerosis - 406 Articles | cancer - 233 Articles | heart disease - 621 Articles | high cholesterol - 483 Articles | stroke - 502 Articles Treatments: | Vytorin - 37 Articles
Helpful?
advertisement
